Securities class action filed against Hims & Hers for alleged investor harm during 2025-2026 period

What happened

A securities class action has been filed against Hims & Hers Health, Inc. and certain officers, covering purchases between August 4, 2025 and July 29, 2026, alleging violations of federal securities laws. This adds a new layer of legal exposure to a company already facing an FTC complaint over privacy and billing practices, as highlighted in the latest 10-Q. The class period includes the sharp stock decline from over $50 in late 2025 to around $28 recently, and overlaps with the company's shift to branded GLP-1 drugs that compressed gross margins from 76% to 64% in Q2 2026. While the company reported Q2 revenue growth of 38% and subscriber growth of 19%, the swing to a net loss of $86.3 million and weak operating cash flow have raised concerns about the sustainability of the business model. The DeepValue report rates HIMS as a WAIT, with no margin of safety at current prices, and this new litigation further clouds the path to margin recovery and cash generation.

Implication

The class action may lead to prolonged legal costs and potential damages, but its financial impact remains uncertain until the case progresses. The company's cash position of $841 million provides some buffer, but liabilities of $3.3 billion and negative free cash flow mean legal distractions can strain execution. The lawsuit's class period overlaps with the period of peak valuation and subsequent decline, suggesting potential merit in claims of misleading statements about growth durability. Investors should monitor for any early court rulings, settlements, or restatements that could indicate the severity of the allegations. Until then, the stock's valuation at 40x EV/EBITDA with deteriorating fundamentals remains unattractive, and the existing thesis of waiting for margin stabilization and FTC resolution is now further complicated.

Thesis delta

The core thesis that HIMS can grow through branded GLP-1s while stabilizing margins and cash flow is unchanged, but this securities class action introduces incremental legal and reputational risk. The WAIT rating becomes even more appropriate, as the lawsuit may signal that management's disclosures during the class period were insufficient, potentially undermining confidence in promised projections. We lower conviction slightly and emphasize that any position should be avoided until there is evidence that legal overhangs are not impairing operating execution or investor trust.